Genscript Biotech (HK:1548)
:1548
Top Page
Genscript Biotech
(1548)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$14.00
▲(13.27% Upside)
Action:ReiteratedDate:12/10/25
Genscript Biotech's overall stock score of 56 is primarily driven by mixed financial performance, with exceptional profitability offset by revenue decline and weak cash flow. Strong earnings call results, highlighting 81.9% revenue growth and a solid cash position, provide a positive lift. However, bearish technical indicators showing a downward trend and a concerning negative P/E ratio weigh heavily on the score, reflecting risks in momentum and valuation.
Positive Factors
Revenue Growth
Strong revenue growth across all segments indicates robust demand and successful execution of business strategies, supporting long-term expansion.
Negative Factors
Net Loss Due to Legend Biotech
Ongoing losses from Legend Biotech strain overall profitability, potentially impacting financial stability and investor confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Strong revenue growth across all segments indicates robust demand and successful execution of business strategies, supporting long-term expansion.
Read all positive factors
Genscript Biotech (1548) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$26.89B
Dividend YieldN/A
Average Volume (3M)11.61M
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees5,568
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.80
Shares Outstanding2,188,046,400
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.64
Price to Sales (P/S)4.64
P/FCF Ratio-38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.40Price Target Upside40.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$805.93M
Genscript Biotech Business Overview & Revenue Model
Company Description
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and i...
How the Company Makes Money
Genscript Biotech generates revenue primarily through its diverse offerings in gene synthesis, protein production, and antibody services. The company operates on a B2B model, where it serves a wide array of clients including academic institutions,...
Genscript Biotech Earnings Call Summary
Earnings Call Date:Aug 17, 2025
(Q2-2025)
| Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.Positive Updates
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Negative Updates
Net Loss Due to Legend Biotech
The Group's net loss was approximately USD 24.5 million, significantly impacted by Legend Biotech's current period loss and the amortization impact of a USD 3.2 billion variation increase when it was deconsolidated in 2024.
Read all updates
Q2-2025 Updates
Positive
Negative
Record Revenue Growth
The Group's revenue increased by 81.9% year-over-year to approximately USD 519 million. All three segments achieved growth, with GenScript Life Science growing by 11.3%, ProBio by 511%, and Bestzyme by 8.4%.
Read all positive updates
Company Guidance
During the 2025 interim results conference call, GenScript provided detailed guidance on their financial and operational performance for the first half of the year and projections for the second half. The company reported an impressive 82% year-over-year revenue growth, with the adjusted profit from continuing operations significantly increasing to approximately USD 180 million. Key highlights included the GenScript Life Science business achieving an 11.3% revenue increase to USD 248 million, and ProBio exhibiting a robust 511% growth to USD 247 million. Bestzyme also experienced a revenue rise of 8.4% to USD 28.3 million. Legend Biotech's CAR-T product, CARVYKTI, treated over 7,500 patients and saw a 136% increase in net trade sales to USD 439 million. GenScript forecasts continued growth, with GenScript Life Science's full-year revenue expected to increase by 13% to 15% and anticipates ProBio to recognize additional milestone payments in the second half. The company maintains a strong cash position of USD 970 million, supporting global expansion and R&D initiatives. Additionally, GenScript remains committed to advancing ESG initiatives, earning a silver medal from EcoVadis and an AA rating from MSCI ESG, reflecting their dedication to sustainability and governance.Genscript Biotech Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
75
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 551.89M | 594.49M | 839.53M | 625.70M | 490.10M | 390.85M |
| Gross Profit | 285.77M | 272.13M | 270.63M | 304.08M | 282.52M | 255.89M |
| EBITDA | 397.29M | 70.43M | -249.42M | -389.04M | -477.27M | -174.71M |
| Net Income | 3.11B | 2.96B | -95.48M | -226.85M | -358.71M | -204.94M |
Balance Sheet | ||||||
| Total Assets | 5.43B | 5.28B | 3.39B | 2.55B | 2.23B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 938.36M | 621.18M | 1.93B | 1.46B | 1.41B | 772.38M |
| Total Debt | 548.52M | 723.74M | 416.99M | 349.80M | 156.45M | 55.00M |
| Total Liabilities | 1.01B | 954.91M | 1.34B | 1.18B | 846.17M | 631.82M |
| Stockholders Equity | 4.42B | 4.32B | 1.39B | 1.01B | 1.05B | 901.71M |
Cash Flow | ||||||
| Free Cash Flow | 200.49M | -72.27M | -444.62M | -336.40M | -269.83M | -272.97M |
| Operating Cash Flow | 232.62M | 75.65M | -286.91M | -120.29M | -136.79M | -151.09M |
| Investing Cash Flow | -98.64M | -1.46B | -357.73M | -443.30M | -212.55M | -100.17M |
| Financing Cash Flow | 26.40M | 66.52M | 1.07B | 419.32M | 902.14M | 624.20M |
Genscript Biotech Technical Analysis
Positive
12.36
Price Trends
11.95
Positive
13.21
Negative
14.90
Negative
Market Momentum
-0.11
Negative
61.09
Neutral
76.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1548, the sentiment is Positive. The current price of 12.36 is above the 20-day moving average (MA) of 11.30, above the 50-day MA of 11.95, and below the 200-day MA of 14.90, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 61.09 is Neutral, neither overbought nor oversold. The STOCH value of 76.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1548.
Genscript Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$48.87B | 20.04 | 6.54% | 1.57% | 12.35% | 34.32% | |
63 Neutral | HK$144.73B | 11.12 | 10.55% | ― | 16.90% | 63.11% | |
63 Neutral | HK$57.11B | 18.63 | 11.48% | 1.04% | 14.50% | -19.24% | |
56 Neutral | HK$26.89B | -6.48 | -12.75% | ― | ― | ― | |
55 Neutral | HK$4.17B | 7.02 | 4.48% | ― | -8.11% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$2.24B | 24.35 | 1.14% | ― | -3.04% | -37.18% |
* Healthcare Sector Average
HK:1548
Genscript Biotech
12.36
2.56
26.12%
HK:2269
Wuxi Biologics (Cayman)
34.98
16.70
91.36%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
20.98
9.36
80.47%
HK:1521
Frontage Holdings Corp.
1.10
0.02
1.85%
HK:1873
Viva Biotech Holdings
1.97
0.78
65.55%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
102.50
60.54
144.28%
Genscript Biotech Corporate Events
Genscript Biotech Grants Share Awards to Directors
Dec 15, 2025
Genscript Biotech Corporation announced the grant of 36,314 share awards to two independent non-executive directors under its 2019 RSU Scheme. The awards, which have no purchase price or performance targets, aim to align the directors’ inter...
Genscript Biotech Updates RSU Schemes for Improved Governance
Dec 15, 2025
Genscript Biotech Corporation has announced amendments to its 2019 and 2021 Restricted Share Unit (RSU) Schemes. The changes include the use of treasury shares for settling vested awards, clarifying the structure of awards as restricted share unit...
Legend Biotech Unveils Promising Data at 2025 ASH Meeting
Dec 7, 2025
Legend Biotech Corporation, an associate of Genscript Biotech, announced new long-term clinical and translational data for its CARVYKTI® therapy from the CARTITUDE studies at the 2025 ASH Annual Meeting. This announcement highlights Legend...
Genscript Biotech Announces Q3 2025 Results for Legend Biotech
Nov 12, 2025
Genscript Biotech Corporation announced the financial results for the third quarter of 2025 for its associate, Legend Biotech Corporation, which is listed on the Nasdaq Global Select Market. The announcement highlights that these results pertain s...
Genscript Biotech’s Associate to Present New Data at Hematology Meeting
Nov 3, 2025
Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, will present new data on CARVYKTI® and other pipeline products at the upcoming American Society of Hematology Annual Meeting. This announcement highlights...
Genscript Biotech Reports Strong CARVYKTI® Sales in Q3 2025
Oct 14, 2025
Genscript Biotech Corporation announced that its associate, Legend Biotech, reported approximately $524 million in net trade sales for CARVYKTI® in the quarter ending September 2025. This figure highlights the product’s strong market pe...
Genscript Biotech’s ProBio Receives Significant Sublicense Revenue Boost
Oct 14, 2025
Genscript Biotech Corporation announced that its subsidiary, ProBio, received approximately RMB479.7 million (US$67.5 million) as the second installment of sublicense revenue under an agreement with LaNova Medicines Ltd. This payment is related to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.